Comment on 'Linear energy transfer incorporated intensity modulated proton therapy optimization'.
Comment on 'Linear energy transfer incorporated intensity modulated proton therapy optimization'. Phys Med Biol. 2019 Feb 27;64(5):058001 Authors: Gorissen BL Abstract Cao et al (2018) published an article on inverse planning based on dose-averaged linear energy transfer (LET). Their claim that the problem can be cast as a linear optimization model relies on an incorrect application of the Charnes-Cooper transformation. In this comment we show that their linear model is simlar to one where dose-averaged LET is multiplied with dose, explaining why their model was nonetheless able to improve the LET distribution. PMID: 30811348 [PubMed - in process]
This study recruited two centers with expertise in treating pediatric brain tumors with robotic radiation delivery system photon therapy and proton therapy, respectively, to study the plan quality and the dose deposition characteristics of robotic radiation delivery system photon and intensity modulated proton therapy (IMPT) plans.Methods and MaterialsA total of 18 patients clinically treated with robotic radiation delivery system were planned with intensity-modulated-proton-therapy (IMPT). Cases were planned per the standard of care of each institution but, respected the same planning objectives. The comparison was perfor...
We read with great interest the recent article by DeCesaris et al reporting new clinical outcomes concerning acute skin toxicity in proton therapy (PT).1 This is a timely contribution in light of the increasing interest among the PT community in treating breast cancer2,3 and in preserving a good patient quality of life after treatment.2,4
Conclusion: 45 GyRBE offers effective local control for most patients with group III orbital rhabdomyosarcoma. The delivery of proton therapy to the postinduction tumor volume plus a small margin can mitigate early- and intermediate-term toxicity, but side effects still occur and long-term data are needed to demonstrate the dosimetric advantage of proton therapy. PMID: 31530120 [PubMed - as supplied by publisher]
ProBeam 360° system allows cancer centers to tailor the system to meet their clinical, research, and capacity needs Treatment room options include 360-degree rotating gantries, and fixed beam rooms Provide clinicians a viable path to potential next-generation treatments such as FLASH therapyThis story is related to the following:Clinical Medical Equipment
Abstract Proton beam therapy is a highly conformal form of radiation therapy, which currently represents an important therapeutic component in multidisciplinary management in paediatric oncology. The precise adjustability of protons results in a reduction of radiation-related long-term side-effects and secondary malignancy induction, which is of particular importance for the quality of life. Proton irradiation has been shown to offer significant advantages over conventional photon-based radiotherapy, although the biological effectiveness of both irradiation modalities is comparable. This review evaluates current d...
PALO ALTO, Calif., Sept. 16, 2019 -- (Healthcare Sales &Marketing Network) -- Varian (NYSE: VAR) today announced its ProBeam 360° proton therapy system is now available in a multi-room configuration. The ProBeam 360° system is the smallest multi-... Devices, Oncology, Product Launch Varian Medical Systems, ProBeam, ProBeam 360, proton therapy, radiotherapy
Abstract To evaluate the clinical impact of biological uncertainties in small field proton therapy due to the assumption of using a constant relative biological effectiveness (RBE) value of 1.1 (RBE-fixed) compared to a variable RBE (RBE-weighted). In this context the impact of the applied range margin was investigated. Eight patients with arteriovenous malformation (AVM) treated with proton radiosurgery were selected due to the small target volume. Dose distributions were compared for RBE-weighted and RBE-fixed. The impact of RBE was assessed using Monte Carlo (MC) dose calculations for stereot...
Children with cancer who are treated with proton therapy had better outcomes...Read more on AuntMinnie.comComments: 9/12/2019 8:09:08 AMAdmin hgjghjhjfjfgg
Mevion Medical Systems plans to highlight new features and accessories for...Read more on AuntMinnie.comRelated Reading: Mevion, C-Rad integrate proton therapy technology Qfix, Mevion partner on proton therapy systems Mevion, RaySearch extend partnership Mevion takes order from China Mevion lands Mo. order for proton therapy system
Conclusion: The rate of symptomatic brainstem necrosis was extremely low after treatment with PBS-PT in this study. Further work to clarify clinical and dosimetric parameters associated with risk of brainstem necrosis after PBS-PT is needed. PMID: 31512931 [PubMed - as supplied by publisher]